Wedbush Maintains Neutral on Zentalis Pharma, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll maintains a Neutral rating on Zentalis Pharma (NASDAQ:ZNTL) and raises the price target from $12 to $15.

February 28, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll maintains a Neutral rating on Zentalis Pharma and raises the price target from $12 to $15.
The increase in price target from $12 to $15 by a reputable analyst suggests a positive outlook on the stock's value, potentially leading to increased investor interest and a short-term price increase. However, the Neutral rating indicates that the analyst sees the stock as fairly valued at its current price, which might temper the impact of the price target increase.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100